HLF HERBALIFE LTD.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1180262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-44.0%
TTM EPS YoY-45.7%
Revenue 3-yr CAGR1.6%
Net income 3-yr CAGR-1.2%
Margins
Gross margin77.6%
Operating margin9.6%
Net margin3.4%
FCF margin6.4%
EBITDA margin11.9%
Returns
ROE—
ROA6.4%
ROIC (approx.)33.3%
Asset turnover1.89x
Leverage & solvency
Liabilities / assets114.0%
Debt / equity—
Current ratio1.19x
Interest coverage2.90x
Cash quality & payout
Operating cash flow / net income2.20x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.35B | $1.33B | $1.32B | $1.28B | $1.27B | $1.26B | $1.22B | $1.21B |
| Cost of revenue | $306.10M | $296.30M | $291.10M | $288.30M | $284.20M | $276.90M | $265.20M | $267.50M |
| Gross profit | $1.04B | $1.03B | $1.03B | $994.70M | $989.50M | $982.20M | $956.50M | $939.90M |
| SG&A expense | $432.10M | $436.20M | $431.40M | $336.90M | $413.00M | $408.50M | $400.30M | $436.90M |
| Operating income | $138.50M | $128.30M | $138.40M | $99.80M | $125.80M | $132.60M | $122.80M | $106.50M |
| Interest expense | $31.90M | $37.40M | $46.80M | $57.80M | $51.00M | $53.60M | $52.00M | $66.20M |
| Pretax income | $106.60M | -$3.70M | $91.60M | $50.50M | $74.80M | $79.00M | $70.80M | $52.60M |
| Income tax | $49.50M | $22.80M | $30.40M | -$34.60M | $31.70M | $29.80M | $20.40M | -$125.30M |
| Net income | $58.80M | -$26.30M | $61.90M | $85.40M | $43.20M | $49.30M | $50.40M | $177.90M |
| EBITDA | $169.00M | $159.70M | $167.80M | $129.10M | $156.50M | $163.10M | $153.50M | $135.50M |
| EPS (basic) | 0.56 | -0.25 | 0.60 | — | 0.42 | 0.48 | 0.50 | — |
| EPS (diluted) | 0.55 | -0.25 | 0.57 | — | 0.42 | 0.48 | 0.49 | — |
| Weighted avg. shares (diluted) | 107.30M | 104.50M | 108.40M | — | 104.00M | 103.30M | 102.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $409.20M | $370.50M | $451.20M | $353.10M | $328.00M | $343.60M | $351.00M | $438.10M |
| Receivables | $116.90M | $115.90M | $106.00M | $91.90M | $97.80M | $96.20M | $90.10M | $68.90M |
| Inventory | $508.30M | $507.70M | $494.60M | $511.70M | $512.50M | $513.10M | $488.00M | $475.40M |
| Current assets | $1.23B | $1.17B | $1.25B | $1.14B | $1.11B | $1.10B | $1.09B | $1.14B |
| PP&E, net | $400.80M | $412.50M | $429.30M | $447.70M | $456.70M | $465.80M | $450.30M | $460.20M |
| Goodwill | $128.00M | $125.90M | $99.10M | $100.50M | $101.00M | $101.00M | $89.20M | $87.70M |
| Intangibles | $331.40M | $333.20M | $314.60M | $315.10M | $315.70M | $316.50M | $311.90M | $312.30M |
| Total assets | $2.89B | $2.86B | $2.88B | $2.79B | $2.70B | $2.74B | $2.68B | $2.73B |
| Current liabilities | $1.03B | $973.50M | $1.02B | $1.01B | $999.90M | $1.09B | $1.13B | $1.23B |
| Short-term debt | $12.10M | $12.00M | $9.20M | $20.90M | $20.70M | $168.00M | $218.70M | $283.50M |
| Long-term debt | $1.92B | $2.00B | $1.98B | $1.97B | $2.00B | $1.97B | $1.98B | $1.98B |
| Total debt | $1.93B | $2.02B | $1.99B | $1.99B | $2.02B | $2.14B | $2.19B | $2.26B |
| Total liabilities | $3.29B | $3.32B | $3.31B | $3.30B | $3.30B | $3.39B | $3.42B | $3.53B |
| Shareholders' equity | -$409.60M | -$474.50M | -$441.50M | -$515.10M | -$612.00M | -$660.50M | -$736.00M | -$801.10M |
| Net debt | $1.52B | $1.65B | $1.54B | $1.64B | $1.69B | $1.80B | $1.84B | $1.82B |
| Shares outstanding | 104.80M | 104.80M | 103.40M | 103.30M | 103.20M | 103.10M | 101.60M | 101.20M |
| Cash flow statement | ||||||||
| Operating cash flow | $151.30M | $32.90M | $113.80M | $98.30M | $138.80M | $96.00M | $200,000 | $69.60M |
| Capital expenditure | $18.50M | $11.30M | $10.90M | $18.50M | $20.80M | $22.80M | $18.30M | $25.70M |
| Free cash flow | $132.80M | $21.60M | $102.90M | $79.80M | $118.00M | $73.20M | -$18.10M | $43.90M |
| Investing cash flow | -$18.80M | -$21.60M | -$11.20M | -$18.70M | -$20.60M | -$50.60M | -$18.80M | -$25.60M |
| Financing cash flow | -$90.00M | -$82.70M | $2.00M | -$32.70M | -$130.40M | -$60.20M | -$72.20M | -$9.00M |
| Depreciation & amortization | $30.50M | $31.40M | $29.40M | $29.30M | $30.70M | $30.50M | $30.70M | $29.00M |
| Stock-based compensation | $8.70M | $10.10M | $10.60M | $10.90M | $11.20M | $10.40M | $11.60M | $13.30M |
| Share buybacks | $200,000 | $9.30M | $700,000 | $100,000 | $1.30M | $4.60M | $2.20M | $2.60M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.